Anti-infective vaccination in the 21st century-new horizons for personal and public health

Current Opinion in Microbiology

Volumn 27, Issue , 2015, Pages 96-102

  Scully, Ingrid L ^a   Swanson, Kena ^a   Green, Luke ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; PALIVIZUMAB; ROTAVIRUS VACCINE; WART VIRUS VACCINE; BACTERIAL VACCINE; VIRUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION RISK; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; REVIEW; STAPHYLOCOCCUS AUREUS; VACCINATION; BACTERIAL INFECTIONS; PUBLIC HEALTH; TRENDS; VIRUS DISEASES;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG RESISTANCE, BACTERIAL; HUMANS; PUBLIC HEALTH; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 84940970806     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2015.07.006     Document Type: Review

References (89)

1. Seither R., et al. Vaccination coverage among children in kindergarten-United States, 2013-14 school year. MMWR Morb Mortal Wkly Rep 2014, 63:913-920.
2. Prevention CfDCa Transcript for CDC Telebriefing: Measles in the United States, 2015 January 29, 2015, (available from: http://www.cdc.gov/media/releases/2015/t0129-measles-in-us.html).
3. Clemmons N.S., et al. Measles-United States, January 4-April 2, 2015. MMWR Morb Mortal Wkly Rep 2015, 64:373-376.
4. Pawlowski A., Kallenius G., Svenson S.B. A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines. Vaccine 1999, 17:1474-1483.
5. MacNeil J.R., et al. Current epidemiology and trends in invasive Haemophilus influenzae disease-United States, 1989-2008. Clin Infect Dis 2011, 53:1230-1236.
6. Pilishvili T., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
7. Black S., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004, 23:485-489.
8. Lexau C.A., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
9. Hammitt L.L., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193:1487-1494.
10. Miller E., et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
11. McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011, 10:109-129.
12. Greenberg R.N., et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014, 32:2364-2374.
13. Jackson L.A., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013, 31:3585-3593.
14. Jackson L.A., et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013, 31:3594-3602.
15. Bonten M.J., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015, 372:1114-1125.
16. Skinner J.M., et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29:8870-8876.
17. Ginsburg A.S., Alderson M.R. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today (Barc) 2011, 47:207-214.
18. McNeil L.K., et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013, 77:234-252.
19. Trotter C.L., Maiden M.C. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009, 8:851-861.
20. Campbell H., et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847.
21. Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31:101-107.
22. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
23. Saunders N.J., et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol Microbiol 2000, 37:207-215.
24. Wang X., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29:4739-4744.
25. McNeil L.K., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27:3417-3421.
26. Murphy E., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
27. Schwarz R., et al. Detecting species-site dependencies in large multiple sequence alignments. Nucleic Acids Res 2009, 37:5959-5968.
28. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015, 57:7-8.
29. In brief: prevention of meningococcus B disease. Med Lett Drugs Ther 2013, 55:97.
30. Hoiseth S.K., et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013, 32:1096-1101.
31. Tondella M.L., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000, 38:3323-3328.
32. Comanducci M., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72:4217-4223.
33. Marc LaForce F., et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl 2):B13-B19.
34. Daugla D.M., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014, 383:40-47.
35. Meningococcal A conjugate vaccine: updated guidance, February 2015. Wkly Epidemiol Rec 2015, 90:57-62.
36. Merck Highlights of Prescribing Information 2015, (available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf).
37. Lowy D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116:1167-1173.
38. Stokley S., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014, 63:620-624.
39. Centers for Disease C and Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59:626-629.
40. Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol 2015, 16:e56.
41. Rotavirus vaccines WHO position paper: January 2013-recommendations. Vaccine 2013, 31:6170-6171.
42. Ruiz-Palacios G.M., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
43. Vesikari T., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
44. Vesikari T., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
45. Kollaritsch H., Kundi M., Giaquinto C., Paulke-Korinek M. Rotavirus vaccines: a story of success. Clin Microbiol Infect 2015, 21:735-743.
46. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999, 48:1007.
47. Glass R.I., et al. Rotavirus vaccines: successes and challenges. J Infect 2014, 68(Suppl 1):S9-S18.
48. Plotkin S.L., Plotkin S.A. A short history of vaccination. Vaccines 2004, 1-15. WB Saunders, Philadelphia. edn 4. S.A. Plotkin, W.A. Orenstein (Eds.).
49. Guzman M.G., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(Suppl):S7-S16.
50. Bhatt S., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
51. Villar L., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.
52. WHO Statement on the 1st Meeting of the IHR Emergency Committee on the 2014 Ebola Outbreak in West Africa 2014, (available from: http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/; cited 04.05.15).
53. WHO Ebola Virus Disease 2015.
54. WHO Ebola Situation Report-22 April 2015 2015, (available from: http://apps.who.int/ebola/current-situation/ebola-situation-report-22-april-2015-0; cited 04.05.15).
55. CIDRAP Recommendations for Accelerating the Development of Ebola Vaccines 2015, 1-84. University of Minnesota.
56. Ledgerwood J.E., DeZure A.D., Stanley D.A., Novik L., Enama M.E., Berkowitz N.M., Hu Z., Joshi G., Ploquin A., Sitar S., et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med 2014.
57. Scully I.L., et al. Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine. Front Immunol 2014, 5:109.
58. Nissen M., Marshall H., Richmond P., Shakib S., Jiang Q., Cooper D., Rill D., Baber J., Eiden J., Gruber W., et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine 2015, 33:1846-1854.
59. Levy J., Licini L., Haelterman E., Moris P., Lestrate P., Damaso S., Van Belle P., Boutriau D. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial. Hum Vaccin Immunother 2015, 11:620-631.
60. Bagnoli F., Fontana M.R., Soldaini E., Mishra R.P., Fiaschi L., Cartocci E., Nardi-Dei V., Ruggiero P., Nosari S., De Falco M.G., et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A 2015, 112:3680-3685.
61. US FDA grants fast-track designation to Sanofi Pasteur's investigational Clostridium difficile vaccine. Clin Infect Dis 2011, 52:i-ii.
62. Donald R.G., et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013, 159(Pt 7):1254-1266.
63. Swanson K.A., et al. Adult vaccination. Hum Vaccin Immunother 2015, 11:150-155.
64. Lowy I., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
65. Practices ACoI Guiding Principles for Development of ACIP Recommendations for Vaccination During Pregnancy and Breastfeeding 2008, (available from: http://www.cdc.gov/vaccines/acip/committee/downloads/preg-principles-2008.pdf; cited 19.03.15).
66. Madhi S.A., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371:918-931.
67. Zaman K., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1555-1564.
68. Swamy G.K., Heine R.P. Vaccinations for pregnant women. Obstet Gynecol 2015, 125:212-226.
69. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239:149-166.
70. American Academy of Pediatrics Committee on Infectious D and C American Academy of Pediatrics Bronchiolitis Guidelines Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134:e620-e638.
71. McLellan J.S., Ray W.C., Peeples M.E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013, 372:83-104.
72. McLellan J.S., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
73. McLellan J.S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117.
74. WHO Global Update on the Health Sector Response to HIV, 2014 2014, 1-174. World Health Organization.
75. Mocroft A., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
76. Palella F.J., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
77. Mann J.K., Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J 2015, 12:3.
78. Chun T.W., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
79. Tongo M., Burgers W.A. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses 2014, 6:3968-3990.
80. Demers K.R., Reuter M.A., Betts M.R. CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev 2013, 254:190-206.
81. Rerks-Ngarm S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
82. Wong A. The HIV pipeline. Nat Rev Drug Discov 2014, 13:649-650.
83. WHO Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections-2008 2012, World Health Organization, Geneva.
84. CDC Sexually Transmitted Disease Surveillance 2012 2013, U.S. Department of Health and Human Services, Atlanta.
85. Sharma H., et al. Microbiota and pelvic inflammatory disease. Semin Reprod Med 2014, 32:43-49.
86. Mabey D.C., et al. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine 2014, 32:1572-1578.
87. Hafner L.M., Wilson D.P., Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014, 32:1563-1571.
88. Pal S., et al. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001, 69:6240-6247.
89. Kari L., et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011, 208:2217-2223.